In addition, several preclinical studies suggest it is efficacious for specific leukemias as well, including blast crisis chronic myelogenous leukemia, Philadelphia chromosome positive ALL, and c-kit positive cancers, as well as other models for multiple myeloma, bladder and breast cancer, glioma, and hepatocellular carcinoma [23, 24, 35, 38–42]. The gene discussed is KIT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.